ChroMedX Submits PCT Patent Application for HemoPalm(TM) Blood Analysis System

(firmenpresse) - CHROMEDX SUBMITS PCT PATENT APPLICATION FOR HEMOPALMTM BLOOD ANALYSIS SYSTEM

TORONTO, ONTARIO -- (August 28, 2015) - ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a PCT (Patent Cooperation Treaty) Patent Application pertaining to the HemoPalmTM Cartridge and Analyzer system called Joint Spectroscopic and Biosensor System for Point-of-Care Testing (PCT/CA2015/050455)

PCT/CA2015/050455 has the potential to effectively extend the lifespan of the Companys issued US Patent pertaining to the HemoPalmTM system, and to provide patent protection outside the US, in particular Europe, China and India. The application claims priority to U.S. Patent Application Nos. 62/114, 700 and 62/006,066.

We are continuing our efforts to expand the Companys Intellectual Property portfolio and are very pleased with the progress made to date, said Dr. Wayne Maddever , ChroMedX Corp., President & CEO

The Companys HemoPalmTM and Ultrafiltration technologies are covered by several issued and pending patents. A list of issued and pending patents can be found on the company's website here: http://www.chromedx.com/intellectual-property/

Other Business

ChroMedX is pleased to announce the engagement of JV Public Relations New York to lead its PR efforts in the United States.

JV Public Relations New York (JVPRNY) is a full-service life science communications agency working to meet the needs of emerging and innovative life science companies. With a collective 30 years of experience, JVPRNYs founder, Janet Vasquez ran award-winning global and local public relations campaigns for an array of life science, pharmaceutical and biotechnology clients, while simultaneously managing highly successful programs for companies in laboratory, medical device, diagnostics/companion diagnostics industries. In addition, the JVPRN team is well-versed in the social media landscape, having designed and implemented social media programs for several JVPRNY clients that span from non-profit consumer health to biotechnology firms.

JVPRNYs goal is to elevate ChroMedX Corps profile in the US markets and engage proactive dialogues on the rising interest of point-of-care testing. JVPRNYs targeted media campaign includes traditional media interviews with print, broadcast and online publications outlets including expert opinion pieces targeting healthcare decision makers.

ChroMedX Corp. also welcomes Shawn Overton as Investor Relations Manager to the Company. Mr. Overtons primary responsibilities will be to manage shareholder correspondence and liaise with the financial community.

The Company recently announced a listing on the US OTC QB Exchange and the closing of a private placement for approximately CAD $1.1MM. ChroMedX announcements can be found here: http://www.chromedx.com/news/

For more information you can visit the ChroMedX Corp. website: www.ChroMedX.com

About ChroMedX Corp.ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Follow ChroMedX Corp.: Facebook: facebook.com/ChroMedXcorpTwitter: www.twitter.com/ChroMedXcorp

Investor Relations:
Shawn Overtond. 647-528-9344o. 647-872-9982 ext. 2TF. 1-844-247-6633 ext. 2soverton(at)chromedx.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-looking Information Cautionary Statement
Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.

Unternehmensinformation / Kurzprofil:
Leseranfragen:
Bereitgestellt von Benutzer: irw
Datum: 28.08.2015 - 22:35 Uhr
Sprache: Deutsch
News-ID 416632
Anzahl Zeichen: 5440

contact information:
Town:

Wien

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 212 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ChroMedX Submits PCT Patent Application for HemoPalm(TM) Blood Analysis System
"
steht unter der journalistisch-redaktionellen Verantwortung von

ChroMedX Corp. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Alle Meldungen von ChroMedX Corp.